Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab in Relapsed/Refractory B-ALL
NCT01685021Phase 2Terminated
- Sponsor
- MorphoSys AG
- Start
- Apr 2013
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by MorphoSys AG. Primary endpoint: Overall Response Rate. Started Apr 2013; status: terminated.
02
Drugs
tafasitamab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT01685021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685021.